The University of Chicago Header Logo

Connection

John Fung to Transplantation, Homologous

This is a "connection" page, showing publications John Fung has written about Transplantation, Homologous.
Connection Strength

2.111
  1. Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin Transplant. 2010 Sep-Oct; 24(5):701-8.
    View in: PubMed
    Score: 0.079
  2. First U.S. near-total human face transplantation: a paradigm shift for massive complex injuries. Plast Reconstr Surg. 2010 Jan; 125(1):111-122.
    View in: PubMed
    Score: 0.076
  3. Near-total human face transplantation for a severely disfigured patient in the USA. Lancet. 2009 Jul 18; 374(9685):203-9.
    View in: PubMed
    Score: 0.073
  4. Percutaneous ultrasound-guided pancreas allograft biopsy: a single-center experience. Transplant Proc. 2005 Dec; 37(10):4436-7.
    View in: PubMed
    Score: 0.057
  5. Revascularization of the gastroduodenal artery in a pancreas allograft from a donor with a replaced right hepatic artery. Transplantation. 2005 Feb 27; 79(4):503.
    View in: PubMed
    Score: 0.054
  6. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation. 2003 Sep 15; 76(5):827-32.
    View in: PubMed
    Score: 0.049
  7. Minimal evidence of transdifferentiation from recipient bone marrow to parenchymal cells in regenerating and long-surviving human allografts. Am J Transplant. 2003 Sep; 3(9):1173-81.
    View in: PubMed
    Score: 0.049
  8. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003 May 03; 361(9368):1502-10.
    View in: PubMed
    Score: 0.048
  9. Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation. 2002 Nov 15; 74(9):1290-6.
    View in: PubMed
    Score: 0.046
  10. The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival. Transplant Proc. 2000 Sep; 32(6):1197-8.
    View in: PubMed
    Score: 0.040
  11. Bacterial translocation in clinical intestinal transplantation. Transplant Proc. 2000 Sep; 32(6):1210.
    View in: PubMed
    Score: 0.040
  12. Posttransplant lymphoproliferative disorders in small bowel allograft recipients. Transplant Proc. 2000 Sep; 32(6):1213.
    View in: PubMed
    Score: 0.040
  13. The long-term efficacy of multivisceral transplantation. Transplant Proc. 2000 Sep; 32(6):1219-20.
    View in: PubMed
    Score: 0.040
  14. Intestinal transplantation for patients with short gut syndrome and hypercoagulable states. Transplant Proc. 2000 Sep; 32(6):1223-4.
    View in: PubMed
    Score: 0.040
  15. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation. 1999 Oct 15; 68(7):1058-61.
    View in: PubMed
    Score: 0.037
  16. Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. Transplant Proc. 1999 Feb-Mar; 31(1-2):700-1.
    View in: PubMed
    Score: 0.035
  17. Quality of life after intestinal transplantation and on total parenteral nutrition. Transplant Proc. 1998 Sep; 30(6):2513-4.
    View in: PubMed
    Score: 0.034
  18. Long-term nutritional monitoring after clinical intestinal transplantation. Transplant Proc. 1998 Sep; 30(6):2515-6.
    View in: PubMed
    Score: 0.034
  19. Nutritional management of intestinal allograft recipients. Transplant Proc. 1998 Sep; 30(6):2517-8.
    View in: PubMed
    Score: 0.034
  20. Combined blockade of CD28/B7 and CD40/CD40L costimulatory pathways prevents the onset of chronic rejection. Transplant Proc. 1998 Jun; 30(4):941-2.
    View in: PubMed
    Score: 0.034
  21. C-C Chemokine Receptor Type 2-Dependent Migration of Myeloid-Derived Suppressor Cells in Protection of Islet Transplants. Transplantation. 2017 08; 101(8):1793-1800.
    View in: PubMed
    Score: 0.032
  22. Perioperative donor bone marrow infusion in recipients of organ allografts. Transplant Proc. 1997 Jun; 29(4):2192-3.
    View in: PubMed
    Score: 0.032
  23. Chimerism after organ transplantation. Curr Opin Nephrol Hypertens. 1997 May; 6(3):292-8.
    View in: PubMed
    Score: 0.031
  24. Experimental animal model of graft-versus-host disease (GVHD) after small-bowel transplantation: characteristics of the model and application to developing treatment strategies. Transplant Proc. 1997 Feb-Mar; 29(1-2):700.
    View in: PubMed
    Score: 0.031
  25. Cytokine profile in graft-versus-host disease after small bowel transplantation. Transplant Proc. 1996 Oct; 28(5):2455.
    View in: PubMed
    Score: 0.030
  26. Concomitant infusion of unmodified donor bone marrow into unconditioned recipients of intestinal allografts. Transplant Proc. 1996 Oct; 28(5):2757-8.
    View in: PubMed
    Score: 0.030
  27. Daily serum interleukin-6 monitoring in multiple organ transplantation with or without liver allografts. Transplant Proc. 1996 Jun; 28(3):1229-34.
    View in: PubMed
    Score: 0.029
  28. Impact of donor MHC class I or class II antigen deficiency on first- and second-set rejection of mouse heart or liver allografts. Immunology. 1996 May; 88(1):124-9.
    View in: PubMed
    Score: 0.029
  29. Rejection triggers liver transplant tolerance: Involvement of mesenchyme-mediated immune control mechanisms in mice. Hepatology. 2015 Sep; 62(3):915-31.
    View in: PubMed
    Score: 0.028
  30. The role of antibodies in liver graft-induced tolerance in mice: passive transfer of serum and effect of recipient B-cell depletion. Transplant Proc. 1995 Feb; 27(1):511-2.
    View in: PubMed
    Score: 0.027
  31. Evidence for early Th 2 T cell predominance in xenoreactivity. Transplantation. 1993 Oct; 56(4):905-11.
    View in: PubMed
    Score: 0.025
  32. Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway. Transplantation. 2013 Jul 15; 96(1):17-24.
    View in: PubMed
    Score: 0.024
  33. Liver graft induced donor specific unresponsiveness without class I and/or class II antigen differences. Transplant Proc. 1993 Feb; 25(1 Pt 1):362-3.
    View in: PubMed
    Score: 0.023
  34. The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells. Blood. 2013 Mar 07; 121(10):1760-8.
    View in: PubMed
    Score: 0.023
  35. Comparison of the small intestine after multivisceral transplantation with the small intestines transplanted with portal or caval drainage. Transplant Proc. 1992 Jun; 24(3):1143-4.
    View in: PubMed
    Score: 0.022
  36. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis. 1992 Feb; 12(1):51-9.
    View in: PubMed
    Score: 0.022
  37. Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. Transplant Proc. 1991 Dec; 23(6):3238-9.
    View in: PubMed
    Score: 0.022
  38. Combined liver-kidney transplants: allosensitization and recipient outcomes. Transplantation. 2011 Jun 15; 91(11):1286-92.
    View in: PubMed
    Score: 0.021
  39. Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology. 2011 Mar; 53(3):1007-19.
    View in: PubMed
    Score: 0.020
  40. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc. 1991 Feb; 23(1 Pt 1):14-21.
    View in: PubMed
    Score: 0.020
  41. The effect of thymus transplantation on allograft rejection in thymectomized bone marrow chimeras. Transplant Proc. 1990 Dec; 22(6):2536-8.
    View in: PubMed
    Score: 0.020
  42. Glucose balance of porcine liver allograft is an important predictor of outcome. J Surg Res. 2011 Dec; 171(2):851-8.
    View in: PubMed
    Score: 0.020
  43. A critical role of TRAIL expressed on cotransplanted hepatic stellate cells in prevention of islet allograft rejection. Microsurgery. 2010 May; 30(4):332-7.
    View in: PubMed
    Score: 0.019
  44. FK 506 dosage in human organ transplantation. Transplant Proc. 1990 Feb; 22(1):23-4.
    View in: PubMed
    Score: 0.019
  45. Liver allograft rejection: an overview of morphologic findings. Am J Surg Pathol. 1990; 14 Suppl 1:49-63.
    View in: PubMed
    Score: 0.019
  46. ICAM-1 expressed on hepatic stellate cells plays an important role in immune regulation. Microsurgery. 2007; 27(4):328-32.
    View in: PubMed
    Score: 0.015
  47. Cotransplanted hepatic stellate cells enhance vascularization of islet allografts. Microsurgery. 2007; 27(4):324-7.
    View in: PubMed
    Score: 0.015
  48. In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology. 2006 Nov; 44(5):1171-81.
    View in: PubMed
    Score: 0.015
  49. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology. 2006 Aug; 44(2):489-501.
    View in: PubMed
    Score: 0.015
  50. Expanding the donor pool: safe transplantation of a cadaveric liver allograft with a 10 cm cavernous hemangioma--a case report. Liver Transpl. 2006 Apr; 12(4):687-9.
    View in: PubMed
    Score: 0.015
  51. Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. Transpl Int. 2003 Dec; 16(12):849-56.
    View in: PubMed
    Score: 0.012
  52. Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation. 2003 Aug 27; 76(4):721-9.
    View in: PubMed
    Score: 0.012
  53. Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from FLT3L-treated donors. Transplantation. 2001 Oct 27; 72(8):1423-32.
    View in: PubMed
    Score: 0.011
  54. Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. Transplant Proc. 2001 Feb-Mar; 33(1-2):129-30.
    View in: PubMed
    Score: 0.010
  55. Blockade of the CD28/B7 and CD40/CD40L costimulatory pathways does not ameliorate chronic rejection in a mouse aortic allograft model of direct antigen presentation. Transplant Proc. 2001 Feb-Mar; 33(1-2):382.
    View in: PubMed
    Score: 0.010
  56. Neutralization of IL-12 reverses rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with suppression of both cellular and humoral responses. Transplant Proc. 2001 Feb-Mar; 33(1-2):525.
    View in: PubMed
    Score: 0.010
  57. Transfection with genes encoding CTLA4Ig mediated by adenoassociated virus vectors prolongs survival of heart allografts. Transplant Proc. 2001 Feb-Mar; 33(1-2):604.
    View in: PubMed
    Score: 0.010
  58. Liver-derived dendritic cells induce donor-specific hyporesponsiveness: use of sponge implant as a cell transplant model. Cell Transplant. 2001; 10(3):343-50.
    View in: PubMed
    Score: 0.010
  59. Concordant hamster-to-rat liver xenotransplantation leads to hyperlipidemia. Transplant Proc. 2000 Aug; 32(5):1109.
    View in: PubMed
    Score: 0.010
  60. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation. 2000 Jun 15; 69(11):2330-6.
    View in: PubMed
    Score: 0.010
  61. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther. 2000 May; 1(5 Pt 1):430-7.
    View in: PubMed
    Score: 0.010
  62. [Experience of orthotopic liver transplantation from non-heart-beating donors at the University of Pittsburgh Medical Center]. Nihon Geka Gakkai Zasshi. 1999 Dec; 100(12):818-21.
    View in: PubMed
    Score: 0.009
  63. Differential effects of exogenous interleukin-10 on cardiac allograft survival: inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function. Transplantation. 1999 Nov 15; 68(9):1402-9.
    View in: PubMed
    Score: 0.009
  64. An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 1999 Sep 15; 68(5):650-5.
    View in: PubMed
    Score: 0.009
  65. Infusion of donor leukocytes to induce tolerance in organ allograft recipients. J Leukoc Biol. 1999 Aug; 66(2):310-4.
    View in: PubMed
    Score: 0.009
  66. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc. 1999 Aug; 31(5):2028-31.
    View in: PubMed
    Score: 0.009
  67. Prevention and restoration of second-set liver allograft rejection in presensitized mice: the role of "passenger" leukocytes, donor major histocompatibility complex antigens, and host cytotoxic effector mechanisms. Transplantation. 1999 Feb 15; 67(3):444-50.
    View in: PubMed
    Score: 0.009
  68. Recipient pretreatment with mammalian IL-10 prolongs mouse cardiac allograft survival by inhibition of anti-donor T cell responses. Transplant Proc. 1999 Feb-Mar; 31(1-2):115.
    View in: PubMed
    Score: 0.009
  69. Treatment with CTLA4-Ig inhibits rejection of liver allografts from FIt3-ligand-treated donors. Transplant Proc. 1999 Feb-Mar; 31(1-2):453.
    View in: PubMed
    Score: 0.009
  70. Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. Transplant Proc. 1999 Feb-Mar; 31(1-2):646-7.
    View in: PubMed
    Score: 0.009
  71. Hepatocytes and liver nonparenchymal cells induce apoptosis in activated T cells. Transplant Proc. 1999 Feb-Mar; 31(1-2):784.
    View in: PubMed
    Score: 0.009
  72. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Transplant Proc. 1999 Feb-Mar; 31(1-2):1244.
    View in: PubMed
    Score: 0.009
  73. Systemic administration of anti-interleukin-10 antibody prolongs organ allograft survival in normal and presensitized recipients. Transplantation. 1998 Dec 27; 66(12):1587-96.
    View in: PubMed
    Score: 0.009
  74. Donor pretreatment with Flt-3 ligand augments antidonor cytotoxic T lymphocyte, natural killer, and lymphokine-activated killer cell activities within liver allografts and alters the pattern of intragraft apoptotic activity. Transplantation. 1998 Jun 27; 65(12):1590-8.
    View in: PubMed
    Score: 0.009
  75. Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg. 1998 May; 186(5):512-25; discussion 525-7.
    View in: PubMed
    Score: 0.008
  76. The immunolymphatic theory of chronic rejection. Transplant Proc. 1997 Sep; 29(6):2615-6.
    View in: PubMed
    Score: 0.008
  77. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Transplant Proc. 1997 Sep; 29(6):2737-8.
    View in: PubMed
    Score: 0.008
  78. Central venulitis in the allograft liver: a clinicopathologic study. Transplantation. 1997 Jul 27; 64(2):252-7.
    View in: PubMed
    Score: 0.008
  79. Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol. 1997 Feb; 150(2):563-78.
    View in: PubMed
    Score: 0.008
  80. Five-year experience with tacrolimus rescue for renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):306.
    View in: PubMed
    Score: 0.008
  81. Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):310.
    View in: PubMed
    Score: 0.008
  82. Costimulatory molecule-deficient dendritic cell progenitors induce T cell hyporesponsiveness in vitro and prolong the survival of vascularized cardiac allografts. Transplant Proc. 1997 Feb-Mar; 29(1-2):1310.
    View in: PubMed
    Score: 0.008
  83. Treatment of isolated pancreatic islets to reverse pancreatectomy-induced and insulin-dependent type I diabetes in humans: a 6-year experience. Transplant Proc. 1997 Feb-Mar; 29(1-2):746-7.
    View in: PubMed
    Score: 0.008
  84. Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant. 1997; 2(2):27-44.
    View in: PubMed
    Score: 0.008
  85. Daily serum inflammatory cytokine (tumor necrosis factor-alpha, interleukin-6) monitoring in liver transplantation focusing on allograft rejection: a five-case report. Transplant Proc. 1996 Jun; 28(3):1237-40.
    View in: PubMed
    Score: 0.007
  86. Experience with liver and kidney allografts from non-heart-beating donors. Transplant Proc. 1995 Oct; 27(5):2898.
    View in: PubMed
    Score: 0.007
  87. Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation. 1995 Jul 27; 60(2):158-71.
    View in: PubMed
    Score: 0.007
  88. Propagation of cells expressing donor phenotype (MHC class I, II and Y-chromosome) from the bone marrow of murine liver allograft recipients in response to GM-CSF in vitro. Transplant Proc. 1995 Feb; 27(1):191-3.
    View in: PubMed
    Score: 0.007
  89. Suppression of alloreactive T-cell activation by murine liver F4/80+ accessory cells and kinetics of intrahepatic F4/80+ cells following liver transplantation. Transplant Proc. 1995 Feb; 27(1):520-1.
    View in: PubMed
    Score: 0.007
  90. The liver allograft, chronic (ductopenic) rejection, and microchimerism: what can they teach us? Transplant Proc. 1995 Feb; 27(1):67-70.
    View in: PubMed
    Score: 0.007
  91. Liver and kidney transplantation from non-heart beating donors: the Pittsburgh experience. Transplant Proc. 1995 Feb; 27(1):710-2.
    View in: PubMed
    Score: 0.007
  92. Split tolerance induced by orthotopic liver transplantation in mice. Transplantation. 1994 Jul 15; 58(1):1-8.
    View in: PubMed
    Score: 0.006
  93. Interferon-gamma induced expression of MHC antigens facilitates identification of donor cells in chimeric transplant recipients. Cell Transplant. 1994 Jul-Aug; 3(4):345-8.
    View in: PubMed
    Score: 0.006
  94. Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology. 1994 Apr; 19(4):916-24.
    View in: PubMed
    Score: 0.006
  95. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc. 1993 Dec; 25(6):3337-44.
    View in: PubMed
    Score: 0.006
  96. Induction of donor-specific transplantation tolerance to skin and cardiac allografts using mixed chimerism in (A + B-->A) in rats. Cell Transplant. 1993 Jul-Aug; 2(4):345-53.
    View in: PubMed
    Score: 0.006
  97. Clinical intestinal transplantation. Transplant Proc. 1993 Jun; 25(3):2195-7.
    View in: PubMed
    Score: 0.006
  98. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol. 1993 May; 142(5):1383-91.
    View in: PubMed
    Score: 0.006
  99. Management of intestinal transplantation in humans. Transplant Proc. 1992 Jun; 24(3):1243-4.
    View in: PubMed
    Score: 0.006
  100. Histologic monitoring of human small bowel allografts with clinical correlation. Transplant Proc. 1992 Jun; 24(3):1199-200.
    View in: PubMed
    Score: 0.006
  101. Islet cell allotransplantation in diabetic patients. Histologic findings in four adults simultaneously receiving kidney or liver transplants. Am J Pathol. 1992 May; 140(5):1255-60.
    View in: PubMed
    Score: 0.006
  102. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation. 1992 Feb; 53(2):407-14.
    View in: PubMed
    Score: 0.005
  103. Detection of intrahepatic human islets following combined liver-islet allotransplantation. Pancreas. 1992; 7(4):507-9.
    View in: PubMed
    Score: 0.005
  104. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. Transplant Proc. 1991 Dec; 23(6):3021-2.
    View in: PubMed
    Score: 0.005
  105. Clinical small bowel or small bowel plus liver transplantation under FK 506. Transplant Proc. 1991 Dec; 23(6):3093-5.
    View in: PubMed
    Score: 0.005
  106. Human islet allotransplantation under FK 506. Transplant Proc. 1991 Dec; 23(6):3207.
    View in: PubMed
    Score: 0.005
  107. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. Transplant Proc. 1991 Dec; 23(6):3232-3.
    View in: PubMed
    Score: 0.005
  108. FK 506 used as rescue therapy for human liver allograft recipients. Transplant Proc. 1991 Dec; 23(6):3005-6.
    View in: PubMed
    Score: 0.005
  109. FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery. 1991 Aug; 110(2):357-63; discussion 363-4.
    View in: PubMed
    Score: 0.005
  110. Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol. 1991 Mar; 138(3):609-18.
    View in: PubMed
    Score: 0.005
  111. Allogeneic orthotopic liver transplantation in mice: a preliminary study of rejection across well-defined MHC barriers. Transplant Proc. 1991 Feb; 23(1 Pt 1):705-6.
    View in: PubMed
    Score: 0.005
  112. Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery. 1990 Nov; 108(5):880-9.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.